Vitiligo Prevalence and Patient Burden

John E. Harris, MD, PhD, reviews factors that shape prevalence of vitiligo and also explores the impact of vitiligo on patient quality of life.

Related Content:

Vitiligo: Practical Considerations for a Changing Therapeutic LandscapeVitiligo

Raj Chovatiya, MD, PhD: Takeaways from New Data on Vitiligo, Atopic Dermatitis, HS Treatments

Iltefat Hamzavi, MD: Long-Term Implications of New Data on Upadacitinib for Nonsegmental Vitiligo

Oral Upadacitinib Significantly Reduces Facial, Total Nonsegmental Vitiligo Through 52 Weeks